Drug intelligence / Profile preview

SAR446959

Development stage: Phase 1
Lead developer: Sanofi
Administration: Intraarticular

Overview

SAR446959 is an investigational drug developed by Sanofi for the treatment of knee osteoarthritis. It is currently in Phase 1 clinical trials, with studies underway to assess its safety, tolerability, pharmacokinetics, and pharmacodynamics following intra-articular administration in patients with knee osteoarthritis. The precise mechanism of action has not been disclosed or defined publicly. The drug is classified as a new molecular entity and falls under the antirheumatics class.

Targets

BTK (Bruton tyrosine kinase)

Beyond the preview

Go deeper on SAR446959.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SAR446959.

Explore the full profile